The impact of basal cell carcinoma on the quality-of-life in older patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 Sep 2024
Historique:
received: 26 02 2024
accepted: 15 07 2024
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 17 9 2024
Statut: epublish

Résumé

Basal cell carcinoma (BCC) is the most frequent malignant tumour worldwide and incidences are rising rapidly. BCC grow locally, but can invade surrounding tissues. Little is known concerning their impact on the health-related quality of life (HrQoL), and limited available data reports contradicting results. Measuring HrQoL in BCC patients should be done using disease-specific questionnaires such as the Basal and Squamous cell carcinoma Quality of Life (BaSQoL) questionnaire. The aim of this study was to assess the BCC-related HrQoL by examining all relevant patient, tumour and treatment characteristics to identify the main factors for the BCC-related impact. Specific attention for older BCC patients wass brought forward because of the often complex decisions in this subgroup. Patients ≥ 18 years with a history of BCC were asked to fill in the BaSQoL questionnaire, consisting of 5 subdomains. Multivariable analyses were done using a generalized additive model (GAM) because of the need for incorporation of non-linear functions. The study obtained approval of the Ethics Committee of the Ghent University Hospital (EC/2019/1352). Informed consent was obtained from all subjects. All experiments were performed in accordance with relevant guidelines and regulations. Four hundred patients with a median age of 66 were enrolled. Mean BaSQoL subscores were 0.78 (SD 0.63) for 'behaviour', 1.01 (SD 0.73) for 'diagnosis&treatment', 0.90 (SD 0.73) for 'worries', 0.40 (SD 0.63) for 'appearance' and 1.20 (SD 0.75) for 'other people', illustrating the low to moderate impact of BCC on the HrQoL. A GAM with subsequent ANOVA testing was done for all relevant variables. In 4 out of 5 BaSQoL subdomains 'age' showed a significant correlation ('behaviour' p = 0.007; 'diagnosis&treatment' p = 0.026; 'worries' p = 0.003; 'appearance' p = 0.008). Lower BaSQoL scores were seen in older patients, meaning less BCC-impact on their HrQoL. There was a clear non-linear correlation between BaSQoL scores and age, illustrating that the impact of BCC on the HrQoL shows a rapid decrease starting around the age of 70. This study is the first to illustrate the relation between the BCC-related HrQoL and the age of patients with the use of a disease-specific HrQoL instrument. We found a lower BaSQoL score in older adults, with a specific age group of interest starting around the age of 70-75. This is an argument for a potential wait-and-see strategy for BCC in these patients.

Identifiants

pubmed: 39289416
doi: 10.1038/s41598-024-67740-0
pii: 10.1038/s41598-024-67740-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21739

Subventions

Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S69921N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12Y2420N

Informations de copyright

© 2024. The Author(s).

Références

Flohil, S. C., de Vries, E., Neumann, H. A. M., Coebergh, J. W. W. & Nijsten, T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta. Derm. Venereol. 91(1), 24–30 (2011).
doi: 10.2340/00015555-1009 pubmed: 21264452
van Walle L. Huidige situatie, trends & toekomst.
Van Coile, L. et al. The therapeutic dilemma of basal cell carcinoma in older adults: A review of the current literature. J. Geriatr. Oncol. 14(3), 101475 (2023).
doi: 10.1016/j.jgo.2023.101475 pubmed: 36990928
Hoorens, I. et al. Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: A cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 36(11), e906–e907 (2022).
doi: 10.1111/jdv.18349 pubmed: 35734826
Peris, K. et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 192, 113254 (2023).
doi: 10.1016/j.ejca.2023.113254 pubmed: 37604067
Siegel, J. A., Chren, M. M. & Weinstock, M. A. Department of veterans affairs keratinocyte carcinoma chemoprevention trial group. correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study. J. Am. Acad. Dermatol. 75(3), 639–642 (2016).
doi: 10.1016/j.jaad.2016.05.008 pubmed: 27543222
Rhee, J. S. et al. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope. 117(3), 399–405 (2007).
doi: 10.1097/MLG.0b013e31802e2d88 pubmed: 17334300 pmcid: 1847346
Chen, T., Bertenthal, D., Sahay, A., Sen, S. & Chren, M. M. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch. Dermatol. 143(11), 1386–1392 (2007).
doi: 10.1001/archderm.143.11.1386 pubmed: 18025362
Sanz Aranda, E., Bernal Martínez, Á. J., Reola Ramírez, E., Perales Enguita, A. & Martí Ayats, J. M. Quality of life in patients of advanced age with basal cell carcinoma: Analysis and implications for approach to treatment. Actas Dermosifiliogr. 113(5), 536–539 (2022).
doi: 10.1016/j.ad.2021.02.022 pubmed: 35697417
Waalboer-Spuij, R., Hollestein, L. M. & Nijsten, T. E. C. Group LV. satisfaction with information provision and health-related quality of life in basal and squamous cell carcinoma patients: A cross-sectional population-based study. Acta Derm. Venereol. 99(10), 933–934 (2019).
doi: 10.2340/00015555-3226 pubmed: 31120545
Gordon, L. G., Lindsay, D., Olsen, C. M. & Whiteman, D. C. Health utilities and health-related quality of life of patients with keratinocyte skin cancers. JEADV Clin. Pract. https://doi.org/10.1002/jvc2.227 (2023).
doi: 10.1002/jvc2.227
Charlson, M., Szatrowski, T. P., Peterson, J. & Gold, J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47(11), 1245–1251 (1994).
doi: 10.1016/0895-4356(94)90129-5 pubmed: 7722560
Linos, E. et al. Treatment of nonfatal conditions at the end of life: Nonmelanoma skin cancer. JAMA Int. Med. 173(11), 1006 (2013).
doi: 10.1001/jamainternmed.2013.639
Waalboer-Spuij, R., Hollestein, L. M., Timman, R., van de Poll-Franse, L. V. & Nijsten, T. E. Development and validation of the basal and squamous cell carcinoma quality of life (BaSQoL) questionnaire. Acta Derm. Venereol. 98(2), 234–239 (2018).
doi: 10.2340/00015555-2806 pubmed: 28952653

Auteurs

Laura Van Coile (L)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Annick Meertens (A)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Department of Public Health and Primary Care, Interuniversity Centre for Health Economics Research (I-CHER), Ghent University, Ghent, Belgium.

Amber Shen (A)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Rick Waalboer-Spuij (R)

Department of Dermatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Katrien Vossaert (K)

Dermatologie Maldegem (Private Dermatology Practice), Maldegem, Belgium.

Evelien Verhaeghe (E)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Lieve Brochez (L)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Isabelle Hoorens (I)

Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Isabelle.Hoorens@ugent.be.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Isabelle.Hoorens@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH